SUBSCRIBE
SUBSCRIBE

Editas Medicine

What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We’re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer.

We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. We are on an important journey to unlock the full potential of genome editing technology. A journey fueled by our distinct culture, expert team of Editas Medicine ‘Editors’, and the patients we aspire to help around the world. Connect with us to hear about the tremendous progress and scientific advancements we’ve already made and the next breakthrough on the horizon. If you are ingenious, passionate and resilient, come join the revolution. Repairing broken genes is only the beginning.

Stock Symbol: EDIT

Stock Exchange: NASDAQ

11 Hurley Street
Cambridge, Massachusetts 02141 USA
Tel: 617-401-9000
Visit website
Email Us
AWARDS
  • NextGen Class of 2015
NEWS
Business
Editas Medicine CEO Abruptly Resigns, Sends Stocks Plunging
Shares of Cambridge, Mass.-based Editas Medicine are down nearly 20 percent after Chief Executive Officer Katrine Bosley abruptly announced her decision to resign from her role at the company effective March 1.
January 22, 2019
 · 
2 min read
 · 
Alex Keown
Business
Comparing This Year’s Big Biotech IPOs to Previous Years
This year has been a strong one for biotech initial public offerings (IPO). According to the Wall Street Journal, as of mid-October, 55 biotech companies had raised $5.75 billion.
November 1, 2018
 · 
4 min read
 · 
Mark Terry
Business
Is the Biotech Bull Market Over?
It may not have always felt like it, but biotech has been in a bull market mode over the past two-and-a-half years, ever since the iShares Biotechnology Index (IBB) bottomed out at $80.01 on February 9, 2016.
October 29, 2018
 · 
2 min read
 · 
Karl Thiel
Business
Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
October 24, 2018
 · 
5 min read
 · 
Mark Terry
Policy
Broad Institute Fends off CRISPR Patent Lawsuit, at Least for Now
It was a win for the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard University, as a federal court of appeals ruled against the University of California (UC) on CRISPR patents.
September 11, 2018
 · 
4 min read
 · 
Mark Terry
Business
CRISPR Pioneer Jennifer Doudna Opens Lab at Bay Area’s Gladstone Institutes
CRISPR pioneer Jennifer Doudna has set up shop in San Francisco’s Gladstone Institutes. Doudna, a UC Berkley professor credited with the co-discovery of CRISPR-Cas9 genome editing technique, will focus on the development of new ways to implement the gene-editing technique for disease treatment.
September 6, 2018
 · 
3 min read
 · 
Alex Keown
Business
Movers and Shakers for Sept. 4
Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let’s take a look.
September 3, 2018
 · 
5 min read
 · 
Alex Keown
Business
Editas Medicine CMO Plans to Leave the Company at the End of 2018
Cambridge, Mass.-based Editas Medicine, one of the leading CRISPR gene editing companies, is losing its chief medical officer. Gerald Cox will step down from his role at the end of the year.
August 28, 2018
 · 
2 min read
 · 
Alex Keown
Genetown
New Study Says DNA Damage From CRISPR-Cas9 Gene-Editing Has Been Underestimated
Shares of CRISPR Therapeutics (-8 percent), Editas Medicines (-5 percent) and Intellia Therapeutics (-6.7 percent) are all plunging following the release of a report that claimed CRISPR-Cas9 gene editing may cause some dangerous side effects.
July 16, 2018
 · 
3 min read
 · 
Alex Keown
Load More
JOBS
IN THE PRESS
Genetown
Editas Medicine Announces Upcoming September 2023 Investor Events
August 30, 2023
 · 
1 min read
Business
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
August 2, 2023
 · 
9 min read
Genetown
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
July 27, 2023
 · 
5 min read
Business
Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
July 26, 2023
 · 
1 min read
Deals
Editas Medicine Reports Inducement Grant to New Chief Scientific Officer
July 25, 2023
 · 
1 min read
Business
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
July 24, 2023
 · 
5 min read
Genetown
Editas Medicine Announces Pricing of Offering of Common Stock - June 15, 2023
June 14, 2023
 · 
4 min read
Genetown
Editas Medicine Announces Offering of Common Stock - June 14, 2023
June 14, 2023
 · 
4 min read
Genetown
Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial
June 9, 2023
 · 
11 min read
Genetown
Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia
June 6, 2023
 · 
4 min read
Load More